Patent approved in Japan for Isofol’s drug candidate arfolitixorin
GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL). A patent covering the Active Pharmaceutical Ingredient (API), arfolitixorin hemisulfate, in Isofol’s drug candidate has been approved by the the Japanense Patent Office. The Patent is of great strategic significance and will be instrumental in supporting a future commercialization of arfolitixorin in the Japanese market.The patent is valid until 2034. Arfolitixorin is currently being studied in the ongoing global Phase 3 study AGENT , in patients with